• Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | Morningstar

    来源: Buzz FX / 09 5月 2025 05:36:28   America/Chicago

    Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for https://www.morningstar.com/news/business-wire/20250509292050/vir-biotechnology-announces-preliminary-24-week-post-end-of-treatment-data-for-tobevibart-and-elebsiran-combinations-in-chronic-hepatitis-b-from-the-march-study
分享